Federated Hermes’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.1M Buy
+773,744
New +$13.3M 0.02% 649
2024
Q4
– Sell
-598
Closed -$2K – 2193
2024
Q3
$2K Sell
598
-175
-23% -$520 ﹤0.01% 1939
2024
Q2
$2.3K Hold
773
– – ﹤0.01% 1890
2024
Q1
$2.67K Sell
773
-177
-19% -$395 ﹤0.01% 1893
2023
Q4
$1.27K Buy
+950
New +$1.44K ﹤0.01% 1961
2022
Q4
– Sell
-872
Closed -$1K – 2288
2022
Q3
$1K Buy
+872
New +$2.86K ﹤0.01% 2084

Other funds holding TRVI

Federated Hermes's TRVI Position: Q3 2026 in Review

Federated Hermes opened a new position in Trevi Therapeutics (TRVI) in Q3 2026: 773,744 shares worth $11.1M. The stake represents 0.02% of the portfolio and ranks #649 among its holdings. This is a return to the name: Federated Hermes previously reported a position in TRVI as recently as Q3 2024.

Federated Hermes first reported a position in TRVI in Q3 2022 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Federated Hermes held 773,744 shares of Trevi Therapeutics worth $11.1M as of Q3 2026.
  • Trevi Therapeutics was a new Federated Hermes position in Q3 2026.
  • Trevi Therapeutics made up 0.02% of Federated Hermes's portfolio in Q3 2026, its #649 holding.
  • Federated Hermes first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.